Nisa Investment Advisors LLC Reduces Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Nisa Investment Advisors LLC trimmed its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 1.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,838 shares of the company’s stock after selling 2,600 shares during the period. Nisa Investment Advisors LLC’s holdings in Elanco Animal Health were worth $2,468,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Mitchell & Pahl Private Wealth LLC grew its position in shares of Elanco Animal Health by 12.6% in the 4th quarter. Mitchell & Pahl Private Wealth LLC now owns 43,728 shares of the company’s stock valued at $530,000 after buying an additional 4,881 shares during the last quarter. 180 Wealth Advisors LLC grew its position in Elanco Animal Health by 10.4% during the 4th quarter. 180 Wealth Advisors LLC now owns 26,732 shares of the company’s stock worth $324,000 after purchasing an additional 2,525 shares during the last quarter. Harbor Capital Advisors Inc. grew its position in Elanco Animal Health by 24.0% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,084,629 shares of the company’s stock worth $13,135,000 after purchasing an additional 209,734 shares during the last quarter. Everence Capital Management Inc. purchased a new position in Elanco Animal Health during the 4th quarter worth $209,000. Finally, JPMorgan Chase & Co. grew its position in Elanco Animal Health by 76.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Up 0.2 %

ELAN stock opened at $12.09 on Monday. Elanco Animal Health Incorporated has a one year low of $11.11 and a one year high of $18.80. The stock has a market capitalization of $5.97 billion, a PE ratio of 30.21, a price-to-earnings-growth ratio of 2.57 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a fifty day moving average of $12.31 and a 200-day moving average of $13.28.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the business earned $0.18 earnings per share. The business’s revenue for the quarter was down 3.6% compared to the same quarter last year. As a group, analysts expect that Elanco Animal Health Incorporated will post 0.92 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ELAN. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Barclays raised their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. Stifel Nicolaus lowered their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Finally, UBS Group assumed coverage on shares of Elanco Animal Health in a research note on Monday, December 9th. They issued a “buy” rating and a $18.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.43.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.